U.S. markets closed

Rexahn awarded U.S. patent for novel anti-cancer compounds

Rexahn Pharmaceuticals announced that it has significantly expanded its intellectual property around a series of novel anti-tumor quinazoline compounds. Rexahn has been issued patent No. 8,404,698 from the U.S. Patent and Trademark Office, covering these novel quinazoline compounds, their pharmaceutical composition, and method for producing an anti-tumor effect.